Join
Live feed
·
PRReleasevia Quantisnow
Madrigal Pharmaceuticals Inc. logo

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
MDGL· Madrigal Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDGL (Madrigal Pharmaceuticals Inc.) and more on Quantisnow.